Corporate Members

Diamond Elite





Latest News

Walgreens Launches “Feel More Like You” Program to Assist People Living with Cancer Manage the Physical Changes Associated with Treatment

Walgreens has announced that it has launched a new program called Feel More Like You™, developed to help people living with cancer and their caregivers manage the potential physical changes associated with cancer treatment. The exclusive offering will be available at more than 400 Walgreens stores in select markets across the country.  CLICK HERE TO...

FDA approves brentuximab vedotin for previously untreated sALCL and CD30-expressing PTCL

On November 16, 2018, the Food and Drug Administration approved brentuximab vedotin (ADCETRIS, Seattle Genetics Inc.) in combination with chemotherapy for previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified. This is the first FDA approval for previously untreated PTCL...

FDA approves emapalumab for hemophagocytic lymphohistiocytosis

On November 20, 2018, the Food and Drug Administration approved emapalumab (GAMIFANT, Novimmune SA), a monoclonal antibody that binds and neutralizes interferon gamma, for adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. Approval was based on a multicenter, open-label,...


RECORDED WEBINAR Learn about the ways in which CAR T-cell therapy treats blood cancer, what CAR T therapy means for the future of cancer treatment, and the current patient access environment and other key considerations. PRESENTERS Frederick Locke, MD, Moffitt Cancer Center Krishna V. Komanduri, MD, Sylvester Comprehensive Cancer Center Brian Koffman, MD, CLL Society,...

FDA Approves Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

On November 6, the U.S. Food and Drug Administration (FDA) approved elotuzumab (Empliciti) injection for intravenous use in combination with pomalidomide (Pomalyst) and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide (Revlimid) and a proteasome inhibitor. In ELOQUENT-3, a randomized, open-label, phase II trial, elotuzumab...

Who’s Online

There are no users currently online